OncoMatch

OncoMatch/Clinical Trials/NCT07284420

ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis With a Partial Clinical Response to Efgartigimod

Is NCT07284420 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Efgartigimod IV and Empasiprubart IV for achr-ab seropositive generalized myasthenia gravis.

Phase 2RecruitingargenxNCT07284420Data as of May 2026

Treatment: Efgartigimod IV · Empasiprubart IV — This study is part of the ADAPT Forward platform study (NCT07294170). ADAPT Forward is a platform study with the aim to look at how safe different drugs are and how well they work for people with myasthenia gravis. The goal is to find the best therapeutic approach to reduce patients' side effects and improve their quality of life. The aim of this ISA1 is to evaluate the safety and therapeutic relevance of empasiprubart as add-on therapy to efgartigimod in participants with AChR-Ab seropositive generalized myasthenia gravis. The ADAPT Forward master protocol is registered on https://clinicaltrials.gov/study/NCT07294170

Check if I qualify

Extracted eligibility criteria

Prior therapy

Cannot have received: complement inhibitor (zilucoplan, eculizumab, ravulizumab)

Exception: if received within specified washout periods

Current administration of a complement inhibitor or received zilucoplan or eculizumab <2 months or ravulizumab <6 months before the first study drug administration

Structured fields extracted by AI. May contain errors — verify against the official protocol.

US trial sites

  • Profound Research LLC - Carlsbad · Carlsbad, California
  • Visionary Investigators Network · Miami, Florida
  • Dent Neurologic Institute - Amherst · Amherst, New York
  • Erlanger Health System · Chattanooga, Tennessee
  • National Neuromuscular Research Institute · Austin, Texas

Showing up to 5 US sites. See all sites on ClinicalTrials.gov →

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify